Board of Directors

Bjørn Einar Kihl,
Chairman of the Board

Bjørn Einar Kihl (62) has more than 18 years of experience from corporate finance, asset management and investment banking from Hafslund Venture AS, Energy Future Invest AS and Contango Kapital AS. His experience includes board positions in more than 40 private companies. His current board positions include Phonect AS, Energy Future Invest II AS, Catapult Life Science AS, Nordic Cryo Vault AS, Bærums Skiklub and Kihl Invest AS. Mr. Kihl holds a Master of Science (Dipl.Ing.) from Eidgenössische Technische Hochschule Zürich (ETH). Mr. Kihl has served as a director in the company since June 2014 and as the chair since November 2015. He is a Norwegian citizen and resides in Norway and is an independent director of the board. Mr. Kihl holds 27.777 shares in the company through Kihl invest AS.

Gustav Gaudernack,
Member of the Board

Professor and head of Unit for Immunotherapy at Radiumhospitalet from 1995 to 2011. Initiated over 20 clinical studies in cancer vaccination, including the first peptide vaccine study in cancer world wide (mutant RAS). Prof. Gaudernack has more than 50 patents and 15 licenses of monoclonal antibodies, cancer vaccines and cancer diagnostics. Prof. Gaudernack holds 16.000 shares in the company, 10.000 of these though his company Prieta AS.

Peter Sandberg,
Member of the Board

Peter Sandberg has a B.Sc. in Genetics and for the past 30 years he has primarily worked with sales, product launches and branding. He was the General Manager for Fisher Scientific’s Nordic operations for many years, and has experience from BioInvent and as self-employed in GTF AB. Mr. Sandberg has helped to build and develop a variety of companies and has a wide network of contacts throughout the industry. Peter Sandberg works today as Director at SenzaGen AB, Medicon Village Lund.

Bjørn Pedersen,
Member of the Board

Bjørn studied Biochemistry and Cell Biology at the University of Oslo. Since 1974 he Worked in A/S E. Pedersen & Sønn, distributing laboratory supplies. In 1988 he founded Diatec Monoclonals. A/S E. Pedersen & Sønn was sold to Thermo Fisher in 2008 and Bjørn was a part of Fisher Scientific European Management Team until 2012. Bjørn has worked full time in Diatec Monoclonals since 2013. Mr. Pedersen holds 140.734 shares in the company, where 138.434 are though his company Pedro Consulting AS.

Kari Solhus,
Member of the Board

Kari has a B.Sc in biotechnology and chemistry and came to Diatec in 2011. Kari has previous experience as Quality Manager from Eurofins. She holds 2.000 shares in the company. 


23 69 69 66 
40 47 40 78



Gaustadalléen 21, 0349 Oslo

Follow us on social media